home.aspx

 
. home.aspx home.aspx

ARCHIVED NEWS


    GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

    Mar 02, 2020

    Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including m...


    READ MORE

    /news-article.aspx?ID=36713671

    POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

    Mar 02, 2020

    New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to t...


    READ MORE

    /news-article.aspx?ID=36723672

    CHALLENGES FOR TRANSLATING PHARMACOMICROBIOMICS TO PERSONALIZED MEDICINE

    Mar 02, 2020

    A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.Pharmacomicrobiomics is the study of how microbiome variations within and between individuals affect drug action, efficacy, and toxicity. This personalized medicine horizon s...


    READ MORE

    /news-article.aspx?ID=36733673

    TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFIC

    Feb 27, 2020

    Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist pro...


    READ MORE

    /news-article.aspx?ID=36683668

    GILEAD LAUNCHES TWO PHASE III TRIALS OF REMDESIVIR FOR COVID-19

    Feb 27, 2020

    Gilead Sciences, based in Foster City, California, announced it will launch two Phase III clinical trials of its investigational antiviral drug remdesivir in adults diagnosed with COVID-19, the disease caused by the novel coronavirus. The outbreak began in China in December and has since spread thro...


    READ MORE

    /news-article.aspx?ID=36693669

    TAKEDA TAKES AIM AT BECOMING WORLD LEADER IN TREATING CELIAC AND OTHER GI DISORDERS

    Feb 27, 2020

    With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders. Asit Parikh, the head of Takeda’s Gastroenterology Therapeutic A...


    READ MORE

    /news-article.aspx?ID=36703670

    OXYCONTIN MAKER PURDUE PHARMA STARTS AD CAMPAIGN FOR CLAIMS

    Feb 25, 2020

    OxyContin maker Purdue Pharma launched an ad campaign Monday to tell people harmed by their powerful prescription opioid where they can file claims against the company. The $23.8 million campaign is part of Purdue's bankruptcy proceedings as it tries to resolve close to 3,000 lawsuits over its r...


    READ MORE

    /news-article.aspx?ID=36653665

    NOVARTIS COLLABORATES WITH DNDI FOR VISCERAL LEISHMANIASIS DRUG

    Feb 25, 2020

    Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis. LXE408 is an oral treatment for this parasitic disease, which is tra...


    READ MORE

    /news-article.aspx?ID=36663666

TRENDING NEWS


    COVID-19 PANDEMIC: RAPID DELIVERY OF MEDICAL COUNTERMEASURES

    Apr 03, 2020

    Immeasurable efforts are underway to develop treatments and vaccines to address the COVID-19 pandemic. Numerous discovery methods and technologies are currently being explored in clinical trials such as DNA and RNA-based vaccine candidates, adjuvant platform technologies, recombinant nanoparticles, ...


    READ MORE

    /news-article.aspx?ID=37003700

    ASTELLAS PHARMA US AND ASTELLAS GLOBAL HEALTH FOUNDATION COVID-19 PANDEMIC RESPONSE

    Apr 03, 2020

    Astellas Pharma US, ("Astellas") and the Astellas Global Health Foundation are each expanding support for global and local communities fighting COVID-19 by providing up to $2 million of new financial assistance, in aggregate, to meet the urgent demand for resources to help patients, health...


    READ MORE

    /news-article.aspx?ID=37013701

    ELI LILLY, SITRYX SIGN POTENTIAL $880M DEAL TO DEVELOP IMMUNOMETABOLIC MEDICINES

    Apr 01, 2020

    Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines. Under an exclusive global licensing and research collaboration, the companies will involve in the assessment of up to four novel preclinical targets detected by Sitryx. The n...


    READ MORE

    /news-article.aspx?ID=36933693

    GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

    Apr 01, 2020

    GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 hig...


    READ MORE

    /news-article.aspx?ID=36943694

    OSTRICH PHARMA USA PRODUCES ANTIBODIES TO BLOCK THE VIRUS THAT CAUSES COVID-19

    Apr 01, 2020

    Ostrich Pharma USA has announced the successful development of ostrich antibodies to the SARS-CoV-2 virus, the expanding use of those antibodies in Japan, and plans for producing and deploying the antibodies in the U.S. Dr. Yasuhiro Tsukamoto, Dean of the Graduate School of Life and Environmental Sc...


    READ MORE

    /news-article.aspx?ID=36953695

    AZ RECRUITS IMAGINAB IN CD8 IMMUNOPET DEAL

    Mar 30, 2020

    AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical ...


    READ MORE

    /news-article.aspx?ID=36913691

    NEW JERSEY PHARMACEUTICAL COMPANY DONATES 400,000 TABLETS TO LOUISIANA FOR CLINICAL TRIALS IN COVID-19 TREATMENT

    Mar 30, 2020

    Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pa...


    READ MORE

    /news-article.aspx?ID=36923692

    ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

    Mar 26, 2020

    Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, wi...


    READ MORE

    /news-article.aspx?ID=36883688

    GILEAD RESCINDS ORPHAN STATUS REQUEST FOR COVID-19 DRUG

    Mar 26, 2020

    Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over its pricing should it get to market. By asking for orphan status the US pharma sparked concerns that it would charge a premium price for remdesivir, which is being trialled against t...


    READ MORE

    /news-article.aspx?ID=36893689

    XELLIA STARTS STERILE INJECTABLE PRODUCTION AT ONCE VILIFIED U.S. PLANT

    Mar 26, 2020

    After nearly five years and significant investment, commercial production is again underway at a plant that was once the poster-child of pharma production quality failures. Following a January inspection, the FDA has given its nod of approval for Xellia Pharmaceuticals to start manufacturing at the ...


    READ MORE

    /news-article.aspx?ID=36903690

    PHRMA, BIO CAMPAIGN CHAMPIONS MEMBERS' DETERMINATION TO BEAT COVID-19

    Mar 23, 2020

    Together is better, especially when it comes to fighting COVID-19. That’s how pharma and biotech companies are working—and the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO) trade groups want everyone to know. They've launch...


    READ MORE

    /news-article.aspx?ID=36873687

    VALERITAS RECEIVES COURT APPROVAL OF SALE OF BUSINESS TO ZEALAND PHARMA

    Mar 20, 2020

    Valeritas Holdings, Inc.("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced that the U.S. Bankruptcy Court for the District of Delaware (the "Court") approved the sale of substantially...


    READ MORE

    /news-article.aspx?ID=36853685

    AIKIDO PHARMA ADDS ARTIFICIAL INTELLIGENCE LEADER TO ADVISORY BOARD

    Mar 20, 2020

    AIkido Pharma Incorporated (Nasdaq: AIKI) today announced the addition of Andreas Typaldos to the Company's Advisory Board.Mr. Typaldos is a pioneer software and technology entrepreneur, and a private equity investor through a Typaldos Family Office. Currently he is founder and Executive Chairma...


    READ MORE

    /news-article.aspx?ID=36863686

    CORRECTING AND REPLACING CIRCLE PHARMA RAISES $45 MILLION IN SERIES B FINANCING

    Mar 17, 2020

    Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $45 million in a Series B financing. The financing was led by The Column Group, with participation by Nextech Invest. All investors from the prior round ...


    READ MORE

    /news-article.aspx?ID=36823682

    PHASE 1 CLINICAL TRIAL FOR CORONAVIRUS VACCINE BEGINS IN SEATTLE

    Mar 17, 2020

    Phase 1 clinical trials for a coronavirus vaccine have begun at Kaiser Permanente Washington Health Research Institute (KPWHR) has begun, according to a statement from the National Institutes of Health. The investigational vaccination, funded in part by the National Institute of Allergy and Infectio...


    READ MORE

    /news-article.aspx?ID=36833683

    PHARMA SALESFORCES BROUGHT TO A HALT AS CORONAVIRUS SHUTTERS ECONOMY

    Mar 17, 2020

    Late last year, New Jersey drugmaker Amarin won a long-sought U.S. approval for its pill Vascepa, allowing the company to market the drug for reducing heart risk. It was a major milestone for the company, validating the decision to run a lengthy and expensive cardiovascular outcomes study, which had...


    READ MORE

    /news-article.aspx?ID=36843684

SPOTLIGHT

The FDA and Big Pharma agree that SKM could be the answer to the pharma data management mess. KASA is moving ahead, but there are many reasons to embrace SKM now.

RESOURCES

Events